Medical Center Zdrave-1 OOD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Medical Center Zdrave-1 OOD, investigators are evaluating novel anti‑inflammatory therapy for heart failure with preserved ejection fraction, aiming to lower cardiovascular death and improve patient outcomes.
- Evaluation of anti‑inflammatory biologic therapy in HFpEF
- Assessment of cardiovascular outcomes in patients with systemic inflammation
- Integration of novel biomarkers for risk stratification
- Exploration of monthly subcutaneous injection regimens
The research seeks to bring new options to patients with advanced cardiac conditions and reduce the burden of heart disease in the region.
Respiratory Tract Diseases
The pulmonology unit explores cutting‑edge treatments for asthma. It also investigates therapies for COPD. Additionally, antiviral strategies against influenza are being studied, to decrease exacerbations and enhance respiratory health.
- Benralizumab impact on COPD exacerbations
- T2‑high asthma control with novel inhaled agents
- Resistance monitoring for baloxavir in influenza
- Eosinophil‑guided therapy strategies
- Optimization of inhaled corticosteroid/long‑acting β2‑agonist combinations
These investigations aim to provide patients in Kozloduy with more effective, personalized therapies for chronic lung diseases.
Environment and Public Health
Researchers assess virus transmission dynamics. They also examine the influence of environmental factors on respiratory illnesses, supporting community health initiatives.
- Baloxavir susceptibility and household spread
- Effect of air quality on asthma control
- Monitoring of influenza outbreaks in the community
- Evaluation of public‑health interventions for respiratory infections
- Assessment of occupational exposures on lung function
Through these studies, the site contributes to regional health policy and prevention strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB8trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Zdrave-1 OOD
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 5 | Unknown | 2021-04-29 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.